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A B S T R A C T
Background. Up to >80% of sexually active adults will become infected with human papillomavirus (HPV) during their lifetime. Persistent HPV infection can result in cervical, vulvovaginal, penile and anogenital cancer. Clinical studies have shown the efficacy of three doses of quadrivalent HPV-6/11/16/18 L1 virus-like particle (VLP) vaccination, at Day 0, Month 2 and Month 6, to lower the occurrence of HPV infection and its complications. However, immunogenicity and safety of the HPV 
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The role of persistent human papillomavirus (HPV) infection, a sexually transmitted disease, in the development of HPVrelated cancer, namely cervical, vulvovaginal, penile and anogenital cancer, and its pre-malignant condition, has been proven [1] . Virtually all cervical cancers are due to HPV infection, along with 90% of anal cancer and 40% of vulvovaginal and penile cancer [2] . The worldwide HPV prevalence has been estimated to be 10.4% of the female population [3] . Most HPV infections occur within 3-4 years after sexual debut; the lifetime risk is >80% [4] . In 2008, >529 000 cases of cervical and other genital cancers were caused by persistent HPV infection, and at least 275 000 deaths were attributed to cervical cancer [5] . The overall risk of cancer is increased in end-stage renal disease (ESRD) patients, and there is more prevalence of cervical, vulvovaginal and penile cancer in ESRD than in the background population [6] . After kidney transplantation, the overall incidence of cancer significantly increases even further, and most of these cancers are of known or suspected viral etiology, including persistent HPV infection [7] .
Previous study has shown immunogenicity of recombinant synthesis of the HPV L1 protein, the major constituent of the viral capsid, which, when administered with adjuvant, provides a greater immune response than the natural infection [8] . In clinical studies, quadrivalent recombinant HPV genotype 6/11/ 16/18 vaccination has been demonstrated to prevent cervical cancer [9, 10] , vulval and vaginal cancer [11] and anogenital cancer [12] . These efficacy studies support HPV vaccination being integrated in public health care policy. As these studies were performed in non-chronic kidney disease (CKD) subjects, the immunogenicity and safety of the HPV vaccine have never been proven in the CKD population. The cellular and humoral immune responsiveness of the CKD population are impaired by the retention of uremic toxins due to glomerular filtration rate (GFR) reduction [13] . Rationally, in CKD patients, the vaccine efficacy decreases and the effective dose/schedule of the vaccine needs to be adjusted, mostly increased as in hepatitis B virus (HBV) vaccination, in which higher vaccine dosages or an increased number of vaccine injections are recommended [14] . This study aimed to investigate the immunogenicity and safety of quadrivalent recombinant HPV-6/11/16/18 vaccination in CKD stage IV-V-VD patients using the current recommended dose/schedule.
M A T E R I A L S A N D M E T H O D S
This was a prospective single-arm pre-/post-exposure study. The study was approved by the Institutional Review Board for Research (IRB), Chulalongkorn University, Bangkok, Thailand (IRB Number 453/53) and was registered in ClinicalTrials.gov (NCT 298869). CKD stage IV, V and VD patients who met the eligibility criteria were enrolled. The criteria included age from 9-26 years, estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m 2 by Thai eGFR equation [15] , no history of genital/anorectal warts, no history of prior HPV vaccination, no history of severe allergic reaction, not receiving immunoglobulin or blood-derived products within the prior 3 months, no history of splenectomy, no known immune disorders (e.g. connective tissue disease, rheumatoid arthritis), not receiving immunosuppressive agents and no HIV infection. A pregnancy test was performed in female subjects prior to each injection. Patients who had a positive pregnancy test were excluded or deferred completion of vaccine doses.
Vaccination
The vaccine (GARDASILV R , Merck and Co., Inc., Whitehouse Station, NJ) was given as a 0.5-mL intramuscular injection into the deltoid muscle. For hemodialysis (HD) patients, the vaccine injection was on a non-HD day to avoid bleeding complications. Each dose contained 20 mg HPV-6 L1 virus-like particle (VLP), 40 lg HPV-11 L1 VLP, 40 lg HPV-16 L1 VLP and 20 lg HPV-18 L1 VLP, along with 225 lg of amorphous aluminum hydroxyphosphate sulfate adjuvant, given on Day 0, Month 2 and Month 6. All subjects were followed for adverse events for 14 days following each injection.
Multiplexed, competitive LuminexV R immunoassay
All subjects underwent anti-HPV serology testing at Day 0 and Month 7 for anti-HPV-6, -11, -16 and -18 genotypes. Serum-specific neutralizing antibody to HPV genotypes 6/11/ 16/18 were measured using multiplexed, competitive LuminexV R immunoassays (cLIA) (Luminex Corporation, Austin, TX) as previously described [16] . The immunoassay quantitated antibodies to neutralizing epitopes on HPV genotypes 6/11/16/18. Four separate assays, one for each of the HPV genotypes, were performed. The HPV type-specific antibody levels of the reference standards were expressed as milliMerck units (mMu/mL). Seropositivity was defined as anti-HPV serum cLIA levels !20, !16, !20 and !24 mMu/mL for HPV-6, HPV-11, HPV-16 and HPV-18, respectively, as described previously [17] .
Adverse event monitoring
The subjects were observed for at least 60 mins after each injection. On follow-up at Months 2, 6 and 7, the subjects were interviewed to assess vaccine-related adverse events. All adverse events that were possibly, probably or definitely vaccine-related 
Statistical analysis
The geometric mean titers (GMTs) of neutralizing antibodies for each HPV genotype and seroconversion rates were calculated at Day 0 and Month 7. Seroconversion subject for each serotype was defined as seronegative at baseline and seropositive at Month 7 by anti-HPV serum cutoff level. Analysis of variance was used to compare cLIA GMT levels among predialysis, HD and continuous ambulatory peritoneal dialysis (CAPD) patients. A P-value of <0.05 was considered significant. Statistical analysis was performed on a desktop computer, using MedCalc Software version 10 (MedCalc Software bvba, Mariakerke, Belgium).
R E S U L T S

Patients
Sixty CKD cases (male/female: 28/32) received vaccinations ( Table 1 ). There were 3, 43 and 14 pre-dialysis, HD and CAPD cases, respectively. Mean age was 21.5 6 4.6 years. All HD cases had thrice weekly 4-h HD sessions using high-flux synthetic membrane dialyzers. The dialyzers were reused in all HD patients. Glucose-based peritoneal dialysis solution was used in CAPD cases. Average serum creatinine and eGFR in predialysis cases were 10.3 6 4.5 mg/dL and 14. Table 3 ). The immune response generated by the threedose regimen of quadrivalent HPV vaccine was comparable between HD and CAPD, while the cLIA GMTs for pre-dialysis were lower than for the two other dialysis groups (HD and CAPD) (Table 3 ). However, all of the pre-dialysis cases (N ¼ 3) had seroconversion for all HPV genotypes.
Adverse events
None of the patients had acute adverse reactions after receiving vaccine injection. No serious vaccine-related adverse events were observed during 7 months of follow-up. There was no deterioration of renal function or requirement for dialysis initiation after vaccine doses in pre-dialysis subjects.
D I S C U S S I O N
The quadrivalent HPV genotypes 6/11/16/18 have been widely used and recommended for the prevention of persistent HPVrelated diseases and have been integrated into the national vaccination program in some countries. Vaccination with recombinant HPV VLP L1 protein, the major constituent of the viral capsid, induces polyclonal antibody response against epitopes displayed on the VLP surface [18] . Previous studies have shown the neutralizing effect of anti-HPV induced by VLP L1 protein vaccination and have demonstrated that prophylactic administration of quadrivalent HPV VLP L1 capsid proteins is highly efficacious and immunogenic to prevent cervical cancer [9, 10] , vulvar and vaginal cancer [11] , and anogenital cancer [12] . CKD populations have lower immune response to vaccinations. The seroconversion rate in response to HBV vaccination is poor in late CKD stages compared with the general population. In this regard, CKD populations need double doses and more frequent HBV vaccine injections to acquire the protective immunity [14] . Our results showed that VLP of HPV combined with amorphous aluminum hydroxyphosphate sulfate as vaccine adjuvant provides adequate immunogenicity for CKD. The same HPV vaccine doses and schedule recommended for non-CKD produce excellent seroconversion rates in CKD stage IV-V-VD. There were no differences in seroconversion rate at Month 7 among pre-dialysis, HD and CAPD patients. The rate of seroconversion and cLIA GMTs in this CKD cohort was excellent and consistent with previous reports in non-CKD subjects [19] .
Although the magnitude of the HPV genotype immunogenicity response was 46-to 347-fold higher (dependent on genotypes) than the seropositivity cutoff and should be translated to viral protection, as transudation of HPV genotype-specific antibody from serum reach mucosa of external genital surfaces and exert a neutralizing effect on the virus [20, 21] , efficacy studies in CKD are warranted, as in the non-CKD population.
Whether HPV antibody induced by vaccine can be sustainable for HPV protection or whether a booster dose is required to maintain the immunity remains unclear. A study of the HBV vaccine showed that a dialysis population that responds to the vaccine can have a clinically significant HBV infection with <10 mIU/mL decline in anti-HB concentration [22] . For HPV, a study in non-CKD subjects has shown a stabilization of specific HPV genotype 11 and 16 antibody up to 5 years postvaccination, while HPV-6 and -18 antibody levels continued to decline with time after vaccination. Studies in longer-term vaccine efficacy in non-CKD subjects showed maintenance of HPV protection through 5 years of follow-up [23] and an amnestic response of HPV immunity at 5 years post-vaccination [24] . Studies based on a follow-up longer than 5 years post-vaccination are needed in order to observe whether the anti-HPV antibodies decline over time in both non-CKD and CKD patients.
In conclusion, the standard dose/schedule of quadrivalent HPV vaccination provided excellent immunogenicity and safety in CKD stage IV-V-VD. HPV vaccination offers the opportunity to effectively prevent persistent HPV infection in both non-CKD and CKD populations.
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